Portfolio

Innovative antibody engineering for improved therapeutics

Mythic has uncovered a key mechanism governing how antibody drugs interact with target cells. Using this understanding, Mythic is significantly improving upon existing FDA-approved antibody therapies for oncology, both in terms of safety and efficacy.

Visit Website ↗

Pioneering a novel class of mental health therapeutics

Delix is developing a class of novel non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles for the treatment of psychiatric and neurological indications.

Visit Website ↗

Next-gen tools for precision metabolomics

Matterworks is building a machine-learning software platform to enable users of mass spectrometry (MS) instruments to avoid chromatography steps in analyzing metabolomics samples, thereby achieving faster MS performance and covering a significantly broader range of analytes per run.

Visit Website ↗

Pioneering a new category of precision medicine

Tessera is developing large scale "Gene Writing" therapies for repairing deleterious human gene mutations via novel transposon and retrotransposon-based approaches.

Visit Website ↗

Single Cell ​Sample Preparation​ Reengineered

Cellsonics is developing a proprietary SimpleFlow™ technology to enable the first fully automated tissue dissociation workflow from solid tissue to single cells while maintaining native gene expression.

Visit Website ↗

Pushing the boundaries of complex cell analysis via microfluidics

Lightcast is developing a droplet-based instrument for highly multiplexed research workflows. Lightcast’s platform uses light patterns to precisely move the droplets (containing cells, antibodies, etc.) across all of their arrays, allowing for high throughput combinatorial reactions in a programed workflow.

Visit Website ↗

Democratizing DNA synthesis to enable synthetic biology

Switchback Systems is developing a proprietary microfluidic DNA synthesis platform. Their platform enables a dramatic reduction in time and cost, while maintaining high-quality benchtop synthesis of oligonucleotides for a wide range of nucleic acid applications.

Visit Website ↗

Harnessing microbiomics to advance women's health

Freya is revolutionizing women's health through restoration of healthy vaginal microbiomes. Freya's first centers around improving the efficacy of in-vitro fertilization.

Harnessing synthetic biology to target the undruggable

SyntheX has developed a yeast engineering approach that enables the discovery and design of peptide-based drugs with novel modes of action that block tough-to-drug protein-protein interactions (PPIs).

Visit Website ↗

Enabling the at-home medical revolution

Tasso is manufacturing a device for simple, painless at-home blood draws that can support multiple use cases in health, telemedicine (at-home-monitoring), and research (clinical trials).

Visit Website ↗

Platforming into a new era of small molecule inhibitors

Type6 is developing a new class of bifunctional kinase inhibitors to drug a range of historically hard-to-target cancers.  Their rational engineering approach creates highly specific, high avidity molecules.

Streamlining CRISPR-based genome engineering

Inscripta is making biology engineerable with its advanced CRISPR-based platform that offers a fully automated workflow with massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta plans to revolutionize gene-writing, as Illumina has done in gene-reading.

Visit Website ↗

Next-gen protein sequencing platform

Glyphic Biotechnologies is building a next-generation proteomics platform with the depth of a single amino acid sequence and breadth to achieve this over thousand to million heterogeneous peptides. Furthermore, their platform is the only platform that combines both depth and breadth to detect post-translational modifications.

Visit Website ↗

Advancing drug discovery through the power of microfluidics

1859 is leveraging breakthroughs in microfluidics and chemical synthesis to miniaturize the process of drug-screening, thereby enabling better, faster, and cheaper small molecule drug discovery.

Visit Website ↗

General Inception is a company that builds companies

General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation. General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation.

Visit Website ↗

Designer proteins for the health of humans and the planet

Aperiam Bio uses computational methods to stabilize recombinant protein structures, solving a ubiquitous problem in industrial biotechnology. Using their computational approach, Aperiam Bio can produce enzymes with enhanced activity, shelf stability, and an expanded range of compatible reaction conditions, enabling a broad range of protein-based products.

Visit Website ↗

Next-gen gene therapy and genome editing

Replay is creating a novel, ambitious toolkit to deliver large DNA payloads efficiently to any cell type, addressing a rapidly growing cell and gene therapy market. Their platform includes a high-capacity HSV vector for gene delivery and a best-in-class hypoimmunogenic iPSC therapeutic platform.

Visit Website ↗

Harnessing the Power of Digital Biology for Synthetic Biology

Sestina is marshalling a suite of synthetic biology tools to engineer the metabolism of yeast strains to enable the utilization of cheap feedstocks (cellulosic sugar, corn syrup) as food to produce high value chemicals and enzymes.

Visit Website ↗

Groundbreaking tissue engineering for cardiac drug discovery

TARA is pioneering predictive cardiac tissue models to enable faster, safer, and more reliable development of new medicines. TARA is focused on three critical areas including cardiac toxicology, precision cardiology, and heart failure drug discovery.

Visit Website ↗

Pioneering novel mental health treatments

Bolstered by FDA’s breakthrough therapy designation, Compass is developing patent-protected psilocybin formulations for the treatment of intractable mood disorders.

Visit Website ↗

Advancing a novel class of microbiome therapeutics

Finch is developing full spectrum and rationally selected microbiome-based drugs for the treatment of recurrent Clostridium Difficile infections, Autism Spectrum Disorder, Hepatitis B, Ulcerative Colitis, Crohn's disease, and several more.

Visit Website ↗

Ushering the next generation of single-cell research

10X Genomics’ products combine hardware, chemistry, and software to power research across the life sciences with single cell, spatial, and in situ products. Their technology allows customers to resolve complex biology across the fields of oncology, immunology, neuroscience, and more.

Innovating DNA synthesis for breakthrough discoveries

Twist Bioscience manufactures high-quality synthetic DNA and DNA products at a rate significantly faster and cheaper than their competitors. Twist caters to customers in a wide range of industries including medicine, agriculture, industrial chemicals, and data storage.

Making biology easier to engineer

Ginkgo Bioworks specializes in using genetic engineering to produce bacteria with industrial applications. They design organisms for customers in a range of industries including medicine and agriculture. Ginkgo Bioworks went public in September 2021 (NYSE: DNA).

Expanding the capabilities of antibody therapeutics

AxioMx has developed phage display into a viable technology for everyday production of monoclonal antibodies. In 2015, they were acquired by Abcam to break into new markets such as infectious diseases, toxins, membrane bound proteins, and other challenging areas.

Accelerating innovation in biomarker driven diagnostics

CD Diagnostics is focused on analyzing biomarker profiles for various clinical conditions in synovial fluid and creating diagnostic assays. In 2016, Zimmer Biomet acquired CD Diagnostics in order to accelerate the pace of innovation in musculoskeletal diagnostics.

Enabling the exploration of complex genetic landscapes

QuantaLife developed ddPCR (Droplet Digital Polymerase Chain Reaction), a high-resolution platform for validating next-generation sequencing discoveries. In 2011, Bio-Rad acquired QuantaLife to expand state of the art methods of quantitative PCR for a variety of molecular diagnostic applications.

Re-writing the rules for biotherapeutic discovery

RubrYc uses molecular engineering principles to modulate therapeutically relevant protein interactions using their Interface Discovery Engine™. Their platform provides unprecedented opportunities to modulate historically challenging protein interactions and access novel targets.

Groundbreaking vascular-targeted biotherapeutics

Angiex is developing groundbreaking antibody-based therapeutics against a novel target, TM4SF1 (Transmembrane-4 L Six Family member 1). TM4SF1 is a glycoprotein expressed on many human epithelial tumor cells that can act as a dual tumor vessel and tumor cell therapeutic target.

Expanding capabilities of high-definition spatial proteomics

Ionpath delivers high-definition spatial proteomics to revolutionize tissue imaging and analysis for accelerated discovery. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC (immunohistochemistry analysis), enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.

Accelerating microbial product discovery and development

General Automation Lab Technologies (GALT) is developing advanced products to help researchers and companies cultivate and study bacteria and other microbes. Their Prospector® high-throughput assay benchtop system can achieve massively parallel isolation and cultivation from complex microbiome samples as well as achieve software-driven imaging, picking, and transferring of single isolates.

Leveraging microbiomics to address inflammatory conditions

AOBiome Therapeutics is focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. The company's portfolio includes multiple clinical-stage programs relating to treating of acne, pediatric and adult eczema (atopic dermatitis), episodic migraines, and allergic rhinitis.

Novel, nutrition-based approach to managing cancer

Filtricine, Inc. is a clinical stage biotechnology company focused on developing a proprietary nutritional regimen that kills cancer cells by eliminating their access to non-essential amino acids.

Finding small molecules to treat "undruggable" diseases

Hexagon Bio is building a first-of-its-kind proprietary genomics database to reveal new secondary metabolites for advanced oncology and infectious disease therapies.

Creating a digital roadmap for precision health

iCarbonX combines genomics with other health factors such as metabolites, bacteria, and lifestyle choices to create an AI driven “digitalized form of life”.

Advancing machine intelligence for medical diagnosis

Imagen is a team of experts in machine learning, healthcare, software engineering, and regulatory affairs, who developed FDA-cleared software that analyzes the content of medical images and detects pathology.

Enhancing biotherapeutic analyses and quality assessments

Intabio develops transformative analytical solutions for efficiency gains across all stages of development and manufacturing for biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. They were recently acquired by SCIEX who hopes to use their combined knowledge to simplify how their customers bring life-saving drugs to market faster.

Innovative, microbiomics driven Diabetes treatment

Driven by microbiomics, Pendulum is developing groundbreaking products to achieve long-term health, starting with type 2 diabetes. Their first product, Pendulum Glucose Control, is a probiotic medical food designed to minimize blood sugar spikes and lower A1C in people with type 2 diabetes taking metformin.

Innovate mental healthcare through new compounds

Perception Neuroscience is an ATAI biopharmaceutical company developing PCN-101 (Arketamine, or R-ketamine) with a vision of providing significantly improved solutions to mental health disorders.

Setting new standards in glaucoma treatment

Ivantis, is expanding patient treatment and improving outcomes through new minimally invasive glaucoma surgical (MIGS) solutions.

Advancing medicine through customized phage therapies

BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in a variety of chronic diseases.

Developing solutions to therapeutic delivery challenges

Xeris leverages novel formulation technology platforms to address issues that arise from water-based delivery systems. They are developing and commercializing proprietary ready-to-use, non-aqueous injectables.